Table 3.

Survival characteristics for standard and high risk IMWG groups sub-stratified with CAGP model

Stratification group	N	HR (95 % CI)	Survival median (months)	3-years outcome (%)	p value (log-rank)
Overall survival
Low risk CAGP	66		38.8	53.8	<0.00799
High risk CAGP	84	1.8 (1.16; 2.80)	22.1	25.1
IMWG standard risk	41		22.8	32.1	<0.1371
IMWG high risk	28	1.6 (0.86; 2.91)	15.8	23.5
IMWG standard risk/low risk CAGP	18		29.2	42.9	<0.4532
IMWG standard risk/high risk CAGP	23	1.4 (0.59; 3.25)	22.8	27.4
IMWG high risk/low risk CAGP	14		16.6	49.9	<0.02836
IMWG high risk/high risk CAGP	14	2.8 (1.07; 7.45)	11.5	8.2
Time to progression
Low risk CAGP	66		13.6	11.5	<0.1939
High risk CAGP	84	1.3 (0.88; 1.88)	13.0	8.7
IMWG standard risk	41		13.2	6.9	<0.7824
IMWG high risk	28	1.1 (0.62; 1.89)	12.0	0
IMWG Standard risk/low risk CAGP	18		12.3	0	<0.9978
IMWG standard risk/high risk CAGP	23	1 (0.48; 2.07)	14.5	9.6
IMWG high risk/low risk CAGP	14		17.7	0	<0.05469
IMWG high risk/high risk CAGP	14	2.3 (0.96; 5.55)	8.0	0
Progression free survival
Low risk CAGP	66		12.6	10.8	<0.06232
High risk CAGP	84	1.4 (0.98; 2.03)	10.2	5.6
IMWG standard risk	41		13.2	6.3	<0.8121
IMWG high risk	28	1.1 (0.62; 1.84)	11.4	0
IMWG standard risk/low risk CAGP	18		12.3	0	<0.9395
IMWG standard Risk/high risk CAGP	23	1 (0.48; 1.97)	13.9	9.1
IMWG high risk/low risk CAGP	14		17.7	0	<0.0325
IMWG high risk/high risk CAGP	14	2.5 (1.05; 5.89)	7.7	0

“Low risk CAGP” group includes patients with “Low expressed” centrosome associated gene pattern. “High risk CAGP” group includes patients with united “High and medium expressed” centrosome associated gene pattern. “IMWG standard risk” group includes patients with ISS III and no adverse FISH or ISS I and t(4;14)/17p13 del; “IMWG high risk” group includes patients with ISS II/III and t(4;14)/17p13 del